| Rank |
Pathway / Axis |
Cancer Cells (↑ / ↓ / ↔) |
Normal Cells (↑ / ↓ / ↔) |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Carbonyl stress / anti-glycation (AGE) |
↓ proteotoxic/carbonyl stress (context-dependent) |
↓ glycation damage (protective) |
P/R |
Cell stress buffering |
Core “chemoprotective” chemistry: nucleophilic scavenging of reactive carbonyls; cancer-direction depends on whether tumor relies on carbonyl-stress adaptation. |
| 2 |
Warburg / glycolysis pressure |
↓ glycolysis flux (model-dependent; high concentration only) |
↔ |
R/G |
Anti-proliferative (subset) |
Frequently reported in vitro with supraphysiologic CAR; translation constrained by rapid serum hydrolysis in humans. |
| 3 |
Mitochondrial function / energetic stress |
↔ / ↑ energetic stress (model-dependent) |
↔ / protective (context-dependent) |
R |
Growth suppression vs resilience |
Direction varies by baseline metabolic state and substrate availability; often secondary to carbonyl/redox effects. |
| 4 |
ROS |
↓ ROS (secondary; context-dependent) |
↓ oxidative damage (protective) |
P/R |
Redox buffering |
Typically described as antioxidant buffering; paradoxical “ROS ↑” cytotoxicity is not a dominant CAR narrative. |
| 5 |
NRF2 (stress-response axis) |
↔ / ↑ cytoprotection (context-dependent; resistance risk) |
↔ / ↑ protective |
G |
Adaptive stress signaling |
If NRF2 is already oncogenic (e.g., KEAP1/NFE2L2-altered tumors), further cytoprotection could be undesirable. |
| 6 |
Ca²⁺ (ER/mitochondria stress coupling) |
↔ (not primary; model-dependent) |
↔ |
R |
Stress modulation (secondary) |
Include only as a secondary axis: CAR’s dominant reported levers are carbonyl/redox/metabolic rather than direct Ca²⁺ channel control. |
| 7 |
Ferroptosis |
↔ (context-dependent) |
↔ |
R/G |
Unclear / secondary |
CAR’s anti-lipid-peroxidation tendency could oppose ferroptosis in some contexts; evidence is not central vs carbonyl/AGE chemistry. |
| 8 |
Clinical Translation Constraint |
Human systemic CAR exposure is constrained by rapid serum hydrolysis (CN1); much in-vitro anti-cancer work uses high µM–mM. Strongest human oncology signal is adjunct/supportive use (e.g., zinc-L-carnosine symptom prevention), not proven tumor regression. |
— |
PK-limited; adjunct-only |
Consider delivery strategies/analogs (e.g., carnosinase-resistant histidine dipeptides) if pursuing systemic pharmacology. |